Diligence memo · auto-generated · as of July 2, 2026
Rythera Therapeutics Inc.
Rythera Therapeutics Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Rythera Therapeutics Inc. operates in Biotechnology, based in DEERFIELD BEACH.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Rythera Therapeutics Inc. has raised $1.3M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.3M on 2022-03-10.
Most recent recorded round closed around 2022-03-10.
Valuation (modeled)modeled
Provath models Rythera Therapeutics Inc. at approximately $22M (range $900K–$108M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.53× the median modeled value of Seed Biotechnology companies in 2022–2024 (207 peers) — value vs value, same stage and era. Issuer reports no revenue, yet is modeled well above niche peers.
Financing rhythm & timingmixed
Last raise 4.3 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 21% of Biotechnology peers (4293 compared).
Modeled value ranks above 30% of those peers.
Closest niche peers: Mesentech Inc., Marlinspike Therapeutics, Inc., Microbial Machines, Inc., Pearl Diagnostics, Inc., Crossfire Medical Inc.
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.